Clinical Scorecard: Impact of Regular Plasmapheresis on a Patient with Severe Renal Impairment Due to Anti-Glomerular Basement Membrane Antibody Disease: A Case Study and Review of Existing Literature

At a Glance

Key Highlights

• Plasmapheresis combined with immunosuppressive therapy may improve renal function in severe cases.
• The patient had a creatinine level of 752 μmol/L and anti-GBM antibody titer of 92.54 RU/mL.
• Persistent plasmapheresis was performed until clearance of pathogenic autoantibodies.
• Renal function was maintained normal during a 5-year follow-up.
• Early intervention is critical for improving outcomes in severe anti-GBM disease.

Guideline-Based Recommendations

Diagnosis

• Diagnosis based on clinical presentation, serological tests for anti-GBM antibodies, and renal biopsy.

Management

• Treatment includes plasmapheresis, cyclophosphamide, and corticosteroids.

Monitoring & Follow-up

• Regular monitoring of renal function and anti-GBM antibody levels.

Risks

• Patients with severe disease have a poor prognosis and may progress to end-stage renal disease.

Patient & Prescribing Data

Critically ill patients with severe renal impairment due to anti-GBM disease.

Early and persistent plasmapheresis is crucial for potential recovery of kidney function.

Clinical Best Practices

• Initiate plasmapheresis promptly in cases of severe anti-GBM disease.
• Combine plasmapheresis with immunosuppressive therapy for better outcomes.
• Monitor kidney function closely during treatment.

Related Resources & Content

• Case Study and Review of Existing Literature